The recombinant shingles vaccine is a two-dose, non-live injection that protects adults over fifty against shingles, a painful rash from the reawakened chickenpox virus. It prevents most shingles and lasting nerve pain, works into the eighties and holds up for over a decade. Population studies link it to fewer dementia diagnoses, a possible but unconfirmed bonus. Short-lived injection-site pain, fatigue or fever are common. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Varicella-zoster virus IgG (immunoglobulin G) antibody | Positive (detectable) | Confirms prior infection; only if chickenpox history is uncertain in younger immunocompromised adults |
| Absolute lymphocyte count | 1.5–3.0 ×10⁹/L | Gauges capacity to respond |
| hs-CRP (high-sensitivity C-reactive protein) | <1.0 mg/L | Baseline inflammation for longevity tracking |
| MoCA (Montreal Cognitive Assessment) score | ≥26/30 | Baseline for cognitive change |
| Blood pressure | <120/80 mmHg | Cardiovascular baseline |
| Anti-gE (glycoprotein E) antibody and T-cell response | No established target; track change from own baseline | Confirms immune response; research assays only |
Cadence: 15-minute observation after each injection, symptom check at 1–3 days, and neurological symptom vigilance through day 42 after each dose; thereafter continuous shingles tracking and cognitive and cardiovascular review every 12 months. No vaccine-specific laboratory monitoring.